New ResMed-sponsored Study Shows Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination
June 04 2018 - 9:05AM
Business Wire
“Bilevel Rescue” study presented at SLEEP 2018
conference
A new study reveals that shifting patients who are struggling
with adherence to positive airway pressure (PAP) therapy to a more
advanced bilevel device in the first 90 days of treatment is an
effective tool for achieving adherence in well more than half of
such cases.
This research, sponsored by ResMed (NYSE: RMD, ASX: RMD), was
presented this week at SLEEP, an annual joint meeting of the
American Academy of Sleep Medicine and the Sleep Research
Society.
Patients diagnosed with sleep apnea are usually prescribed a PAP
device that provides either continuous (CPAP) or auto-adjusting
(APAP) pressure. A bilevel device delivers two distinct pressures,
one for inhalation and one for exhalation. Physicians may prescribe
bilevel for patients who are pressure intolerant or have continued
evidence of apnea at higher pressures.
In this “Bilevel Rescue” study, ResMed compared 1,496
non-compliant patients (as defined by U.S. Medicare guidelines) who
switched to bilevel therapy and found that compliance was achieved
by:
- 58.5 percent of patients who switched
before day 60
- 54.2 percent of patients who switched
between days 60–90
- 56.8 percent of patients overall
“Finding the right mode of therapy made all the difference to
those patients who are struggling with initial adherence to
therapy,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D.
“This strongly suggests that bilevel devices provide a powerful
alternative therapy that physicians and HMEs can utilize to help
improve non-compliant patients’ treatment experience and
outcomes.”
Study details
Compliance with Positive Airway Pressure Therapy after Switching
From CPAP to Bilevel for Non-Compliant OSA Patients: A Big Data
Analysis: A PAP device telemonitoring database was queried for all
patients initiated on CPAP or APAP (automatic positive airway
pressure) therapy between January 1, 2015, and July 31, 2016, who
were not Medicare compliant and switched to bilevel PAP therapy
within the first 90 days of therapy. Anonymous PAP therapy data on
all patients were compared before and after the switch. The
objectives of this study were to compare average daily usage,
adherence (percentage of days where usage was ≥4 hours),
unintentional mask leak, and PAP efficacy (residual events) before
and after switching to bilevel PAP therapy, as well as evaluating
compliance using Medicare guidelines. An Institutional Review Board
(IRB) reviewed this protocol and determined it to be exempt from
IRB oversight.
Read the study’s full abstract here (page A198–199).
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health
company with more than 5 million cloud-connected devices for daily
remote patient monitoring, changes lives with every breath. Its
award-winning devices and software solutions help treat and manage
sleep apnea, chronic obstructive pulmonary disease and other
respiratory conditions. Its 6,000-member team strives to improve
patients’ quality of life, reduce the impact of chronic disease and
save healthcare costs in more than 120 countries. ResMed.com
Medicare compliance, as defined by the U.S. Center for Medicare
& Medicaid Services, requires using PAP 4 or more hours a night
for 70% of nights in a 30-day span within the first 90 days of
therapy.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180604005366/en/
ResMedFor media:Jayme Rubenstein, +1
858.836.6798news@resmed.comorFor investors:David Pendarvis,
+1 858.836.5000investorrelations@resmed.com
ResMed (NYSE:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ResMed (NYSE:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024